Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2013. The report serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibility regarding their interests in the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of share transactions rather than a financial performance report.
Material Changes
The filing details the acquisition of Ordinary Shares by nine senior executives and directors on April 10, 2013, executed through the Company's ShareReward Plan. The transactions occurred at a price of 1535.98 pence per Ordinary Share. Each individual acquired:
- 8 Ordinary Shares under the personal contribution element.
- 8 Ordinary Shares under the matching element (Company contribution).
Individuals involved include Sir Andrew Witty, Mr S Dingemans, Mr S M Bicknell, Mr R G Connor, Mr D S Redfern, Ms C Thomas, Mr P C Thomson, Dr P J T Vallance, Ms E Walmsley, and Mrs V A Whyte.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary on strategy, risks, contingencies, or unusual items. The document is strictly a compliance notification under Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Transaction Date: April 10, 2013.
- Share Price: 1535.98 pence per Ordinary Share.
- Participants: 10 senior executives/directors participated in the ShareReward Plan.
- Volume: Each participant acquired a total of 16 shares (8 personal + 8 company match).
- Notification Date: April 11, 2013.